With 0.1 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.12 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.05 whereas the lowest price it dropped to was $1.95. The 52-week range on IMMP shows that it touched its highest point at $3.34 and its lowest point at $1.66 during that stretch. It currently has a 1-year price target of $7.53. Beta for the stock currently stands at 2.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMMP was down-trending over the past week, with a drop of -8.45%, but this was up by 1.30% over a month. Three-month performance dropped to -11.76% while six-month performance fell -29.60%. The stock lost -16.67% in the past year, while it has lost -18.75% so far this year. A look at the trailing 12-month EPS for IMMP yields -0.23 with Next year EPS estimates of -0.32. For the next quarter, that number is -0.14. This implies an EPS growth rate of 4.19% for this year and -39.89% for next year.
Float and Shares Shorts:
At present, 145.26 million IMMP shares are outstanding with a float of 144.34 million shares on hand for trading. On 2024-11-29, short shares totaled 5.08 million, which was 349.0 higher than short shares on 1730332800. In addition to Mr. Marc Voigt as the firm’s CEO, MD, CFO, Chief Business Officer & Executive Director, Ms. Deanne Miller LLB serves as its COO, General Counsel & Joint Company Secretary.
Institutional Ownership:
Through their ownership of 0.062589996 of IMMP’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMMP since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMMP analysts setting a high price target of 12.0 and a low target of 7.0, the average target price over the next 12 months is 9.5. Based on these targets, IMMP could surge 515.38% to reach the target high and rise by 258.97% to reach the target low. Reaching the average price target will result in a growth of 387.18% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.25339 being high and -$0.34208 being low. For IMMP, this leads to a yearly average estimate of -$0.30407. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
